Clinical Trial Update: To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of KX-826 in male subjects with androgenetic alopecia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia
• Male Pattern Hair Loss

Drugs mentioned

• KX-826

Snippet

Sponsor: Suzhou Kintor Pharmaceutical Inc, | Conditions: Alopecia, Male Pattern Hair Loss | Phase 2 | Status: COMPLETED